指南与共识糖尿病肥胖与代谢综合征

糖尿病患者的代谢功能障碍相关脂肪性肝病(MASLD):需要筛查与早期干预——美国糖尿病协会共识报告

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association.
指南 / 共识 · Diabetes Care · 2025-01-01

该共识报告指出,代谢功能障碍相关脂肪性肝病(MASLD)在2型糖尿病患者中约每3人影响2人,增加代谢功能障碍相关脂肪性肝炎、肝硬化、肝细胞癌及肝相关死亡风险。报告呼吁对糖尿病前期或2型糖尿病(尤其合并肥胖)者筛查肝纤维化并进行风险分层,并阐述命名更迭理由、风险分层方法、治疗与长期监测及多专业协作价值。

要点

  • 2型糖尿病患者中约三分之二存在肝脂肪变,MASLD增加MASH、肝硬化、HCC及肝相关死亡风险。
  • 共识呼吁对糖尿病前期或2型糖尿病者(尤其合并肥胖)筛查肝纤维化并进行风险分层。
  • MASLD还与肝外癌症、动脉粥样硬化性心血管疾病及糖尿病前期向2型糖尿病进展相关。

核心结论

  • 该共识报告呼吁对糖尿病前期或2型糖尿病者(尤其合并肥胖)筛查肝纤维化并进行风险分层,以早期识别MASLD。
  • 广泛采用肝纤维化筛查作为新的诊疗标准,有望使糖尿病前期和2型糖尿病患者未来免于肝硬化。

研究设计与样本

  • 美国糖尿病协会(American Diabetes Association)发布的共识报告。

主要发现

  • 肝脂肪变影响约三分之二的2型糖尿病患者,并增加代谢功能障碍相关脂肪性肝炎、肝硬化、肝细胞癌及总体肝相关死亡风险。
  • MASLD还与肝外癌症、动脉粥样硬化性心血管疾病以及从糖尿病前期向2型糖尿病的进展相关,并对健康相关生活质量产生负面影响。
  • 大多数个体及其医疗保健专业人员仍未意识到MASLD相关的严重肝脏或肝外健康风险以及早期识别的必要性。

关键数值与推荐

  • 共识报告呼吁对糖尿病前期或2型糖尿病者筛查肝纤维化并进行风险分层,尤其当同时存在肥胖时。
  • 共识报告阐述了近期MASLD命名变更的理由、如何最佳进行风险分层、当前治疗与长期监测选项、跨专业疾病管理的价值以及酒精摄入对肝脏健康的影响。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), is a growing but often unrecognized medical problem for people with diabetes (particularly type 2 diabetes, especially when associated with obesity). Liver health has not been at the forefront of complications tracked for disease prevention, as traditionally done for diabetic retinopathy, nephropathy, or neuropathy. However, liver steatosis affects approximately two out of three people with type 2 diabetes and places them at an increased risk for metabolic dysfunction-associated steatohepatitis (MASH), cirrhosis, hepatocellular carcinoma (HCC), and overall liver-related mortality. MASLD is also associated with extrahepatic cancers, atherosclerotic cardiovascular disease, and progression from prediabetes to type 2 diabetes and negatively impacts health-related quality of life. However, most individuals and their health care professionals remain unaware of the severe hepatic or extrahepatic health risks associated with MASLD and the need for early identification. In recognition of this knowledge gap and the rising prevalence of MASLD, this consensus report is a call to action to screen for liver fibrosis and risk stratify people with prediabetes or type 2 diabetes, in particular if obesity is also present. This consensus report explains the rationale for the recent MASLD nomenclature change, how to best risk stratify, current treatment and long-term monitoring options, the value of an interprofessional approach to disease management, and the impact of alcohol intake on liver health. More awareness about the health risks associated with MASLD and broad adoption of screening for liver fibrosis as a new standard of care hold promise for a future without cirrhosis for people with prediabetes and type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025. PMID: 40434108. doi:10.2337/dci24-0094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。